Opportunistic infections after treatment with monoclonal antibodies [Opportunistische infektionen nach therapie mit monoklonalen antikörpern]

被引：8

作者：

Cornely O.A. ^{[1
,2
]}

Ullmann A.J. ^{[1
]}

Karthaus M. ^{[1
]}

机构：

[1] Hämatologie, Onkologie, Klin. der Universität Köln

[2] Hämatologie, Onkologie, Klin. der Universität Köln

来源：

Wiener Medizinische Wochenschrift | 2004年 / 154卷 / 9-10期

关键词：

Cytomegalovirus; Monoclonal antibody; Opportunistic infection; Pneumocystis carinii pneumonia; Prophylaxis; Varizella zoster virus;

D O I：

10.1007/s10354-004-0067-y

中图分类号：

学科分类号：

摘要：

During recent years the therapeutic indications of monoclonal antibodies are on the increase. Most monoclonal antibodies are immunosuppressants. Thus, therapeutic successes are accompanied by an increase of serious infections. Closest cooperation between the haematologist/oncologist and the infectious diseases specialist is a prerequisite for the successful outcome of treatment of the individual patient. Rituximab and alemtuzumab especially pave the way for a variety of opportunistic infections. Prophylactic drugs directed against bacterial infections and invasive fungal infections have not been proven to be useful. Although the efficacy of prophylactic cotrimoxazole against Pneumocystis carinii pneumonia has not been thoroughly examined in this setting, it is usually given at a dose of two double-strength tablets every other day. Whether reactivation of herpes simplex and varizella zoster can be influenced prophylactically has not been studied in randomised trials. In case of fever and detection of cytomegalovirus reactivation preemptive therapy should be given.

引用

页码：209 / 217

页数：8

共 49 条

[1]

Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, 4, pp. 235-242, (2002)

[2]

Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Et al., Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, 9, pp. 876-885, (2004)

[3]

Lipsky P.E., Van Der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group, N Engl J Med, 343, 22, pp. 1594-1602, (2000)

[4]

DiJoseph J.F., Armellino D.C., Boghaert E.R., Khandke K., Dougher M.M., Sridharan L., Et al., Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies, Blood, 103, 5, pp. 1807-1814, (2004)

[5]

Infliximab, Zusammenfassung der Merkmale Eines Arzneimittels, (1999)

[6]

Adalimumab, Zusammenfassung der Merkmale Eines Arzneimittels, (2003)

[7]

Matty F.M., Lee S.J., Fahey M.M., Alyea E.P., Soiffer R.J., Antin J.H., Et al., Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: A cohort study, Blood, 102, 8, pp. 2768-2776, (2003)

[8]

Trastuzumab, Zusammenfassung der Merkmale Eines Arzneimittels, (2002)

[9]

Schmitt B., Wendtner C.M., Bergmann M., Busch R., Franke A., Pasold R., Et al., Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia, Clin Lymphoma, 3, 1, pp. 26-35, (2002)

[10]

Rai K.R., Freter C.E., Mercier R.J., Cooper M.R., Mitchell B.S., Stadtmauer E.A., Et al., Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine, J Clin Oncol, 20, 18, pp. 3891-3897, (2002)

← 1 2 3 4 5 →